GBM patients with short PFST (<3 months) after initiation of Bev therapy (R‐type) showed a high P/C ratio of CD44, whereas patients with longer PFST (≥12 months) after Bev therapy (S‐type) showed a low P/C ratio of CD44. The gene discussed is CD44; the disease is glioblastoma.